Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.50 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 6/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172844 | 0.93 | THRA (0.65) | THRATHRBS1PR1PLA2G2DSMPD1 | |
| SCHEMBL3171378 | 0.88 | THRA (0.61) | THRATHRBS1PR1PLA2G2D | |
| SCHEMBL14274174 | 0.83 | PLA2G2D (0.51) | PLA2G2DSMPD1CNR2 | |
| SCHEMBL4785017 | 0.81 | THRA (0.68) | THRATHRBS1PR1PLA2G2D | |
| SCHEMBL2466292 | 0.80 | THRA (0.70) | THRATHRBS1PR1PLA2G2D | |
| SCHEMBL1171751 | 0.80 | THRA (0.70) | THRATHRBS1PR1PLA2G2D | |
| SCHEMBL2957056 | 0.79 | THRA (0.69) | THRATHRBS1PR1PLA2G2DSMPD1 | |
| SCHEMBL14291418 | 0.79 | THRA (0.49) | THRATHRBS1PR1PLA2G2DSMPD1 | |
| SCHEMBL27669784 | 0.79 | THRA (0.65) | THRATHRBS1PR1PLA2G2D | |
| SCHEMBL28610518 | 0.79 | SMPD1 (0.67) | THRATHRBSMPD1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| EP-2046766-A1 | AGONISTS OF THE SPHINGOSINE- 1- PHOSPHATE RECEPTOR (SLP) | Praecis Pharmaceuticals Incorporated (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080070866-A1 | Chemical compounds | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070866-A1 | Chemical compounds | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070866-A1 | Chemical compounds | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008016674-A1 | AGONISTS OF THE SPHINGOSINE- 1- PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016674-A1 | AGONISTS OF THE SPHINGOSINE- 1- PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | S1PR1, S1PR2, S1PR5 | THRA 593/4885THRB 592/4885S1PR1 1/4885 |
| US-20080070866-A1 | Chemical compounds | S1PR1, S1PR2, S1PR5 | THRA 1994/4885THRB 1533/4885S1PR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.